The acquisition of MRT, with its patented approach to high throughput miniature bioreactor equipment and disposables, expands Pall’s Total Fluid Management(TFM) capabilities in the $1 billion biopharmaceuticals process monitoring and process development market. Terms of the deal were not disclosed.
Speed to market continues to be a critical driver in the biopharmaceuticals industry. High Throughput Process Development (HTPD) is a rapidly emerging approach that enables biotech drug development activities to be accomplished much faster and with less material, said the company.
These systems are proven to simulate the performance of stirred tank bioreactors in both cell culture and microbial fermentation from bench scale (1 to 20L) to much larger scale (up to 200,000L). The disposable bioreactor cassette has 24 individual bioreactors, each of which can be independently controlled and monitored for key parameters, including pH, dissolved oxygen, and temperature.
Eric Krasnoff, chairman and CEO of Pall, said: “We are excited by this acquisition and the increased opportunities it presents for our biotechnology process development and laboratory programs. Customers seek better tools for rapid process development and process monitoring. The addition of MRT further broadens Pall Life Sciences support of customers in this rapidly growing market. We welcome the newest members of the Pall family.”
Stephen Boyer, president of MRT, said: “It is exciting to join Pall and support the rapid growth in our business. More importantly, it enables our customers to exploit on a wider scale, the very significant advantages that the Micro-24 bioreactor technology is bringing to the industry.”